Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 114 participants.

Also called NCT04419467

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 114 participants (enrolled count) (from the registry)
Sponsor
  • CSL Behring Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04419467
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Canada, Israel, New Zealand, Puerto Rico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04419467. Randomized; quadruple masking; primary purpose treatment. Start 2020-09-14 (actual); primary completion 2022-10-24 (actual). Results posted on 2023-12-06.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease
Condition
Diabetic Kidney Disease (DKD)
Intervention (Biological)
CSL346
Intervention (Drug)
Placebo
Lead sponsor
CSL Behring (class: industry)

Record details

Record id
cardio:ct-nct04419467
Content hash
e000ed3e0ffb5bfee98867b22c6082ba811f8ab635a671f8c33df10137cc12f7